Kalvista asks 4 countries to OK sebetralstat as treatment for HAE
Kalvista Pharmaceuticals has submitted applications to regulatory authorities in the U.K., Switzerland, Australia, and Singapore requesting the approval of sebetralstat, an oral, on-demand treatment for hereditary angioedema (HAE) in patients ages 12 and older. The four applications were submitted through the Access Consortium framework, a coalition of…